NewsRoom Articles - Page 83 of 154 - PsychedelicNewsWire (PNW)

WednesdaySep 29, 2021 11:30 am

Why Nuanced Approach in Dealing with Mental Health Issues, Specifically Depression, Is Important

A couple of decades ago, talking about mental health issues in the public was an unspoken taboo. Research on mental health conditions hadn’t come as far as today, and society’s view of mental health wasn’t as open, which led to many people suffering in silence, scared to speak up or seek help. Today discussing how conditions are approached and treated is much more open. Among the most common mental health conditions is depression, a serious ailment that negatively affects how an individual feels, acts and thinks. The disorder causes a loss of interest in activities an person once enjoyed as…

TuesdaySep 28, 2021 1:00 pm

Spiritual Emergencies and Psychedelics: What Are They About?

In the last few years, we’ve seen an increase in the interest in the therapeutic potential of psychedelics, in both nonclinical and clinical settings. Psychedelic substances such as LSD and psilocybin mushrooms possess the ability to cause huge shifts in an individual’s perception and understanding of reality. While seeing things in the world in a new light may be good for an individual’s psyche, it may also trigger psychological distress referred to as a spiritual emergency. What is a spiritual emergency? This refers to a transformative or spiritual crisis in which a person may move toward a greater state of…

MondaySep 27, 2021 12:14 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Mental Health Treatment Innovation

WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19 People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infection Cybin is on a mission to revolutionize mental healthcare A World Health Organization (“WHO”) survey covering 130 countries is calling attention to the fact that today’s demand for mental health, which has been rocked by the COVID-19 pandemic, is only increasing (https://ibn.fm/hzmXq). Cybin (NEO: CYBN) (NYSE American: CYBN) is focused on meeting that need and is committed to finding even more effective…

MondaySep 27, 2021 12:00 pm

Congress to Vote on Psychedelics Research Amendments for Active Military Members

As is so often the case, legislators have introduced various amendments to upcoming legislation for active military members. Those include measures to protect banks that offer their services to state-legal cannabis businesses and those that will facilitate research on the benefits of psychedelics for military personnel. The measure that would enable the defense secretary to award grants for research into the therapeutic potential of psychedelics such as ibogaine, psilocybin and MDMA for military members with PTSD, was filed by Rep. Dan Crenshaw. The grants will be awarded to not-for-profit organizations, academic institutions, and state or federal agencies. Under the measure,…

MondaySep 27, 2021 10:58 am

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Looks Optimally Positioned to Benefit From Continued Growth Within the Psychedelic Wellness Sector

Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough therapy” status in 2018 Denver and Oakland have been among the first US cities to decriminalize the use of psilocybin mushrooms with California currently studying whether to follow suit The psychedelic drugs market is expected to reach a size of $10.75 billion by 2027 When…

FridaySep 24, 2021 1:00 pm

California Activists Receive Approval to Gather Signatures for Psilocybin Legalization Measure

Activists in the state of California have received approval to start gathering signatures for a measure to legalize magic mushrooms. Last week, the office of the attorney general released a title and summary for the initiative, which activists are hoping to include in next year’s ballot. The group behind the proposal, Decriminalize California, is now focused on collecting 623,212 signatures that will allow the initiative, which would legalize the sale of psilocybin under California state law to make the ballot. Advocates are required to gather registered voter signatures in the next 180 days in order to qualify the measure for…

ThursdaySep 23, 2021 2:00 pm

Researchers Focus on Better Understanding Ketamine’s Mechanism of Action

Ketamine has been used for years as an anesthetic and as a horse sedative. In the early 2000s, researchers discovered that the psychedelic possessed antidepressant properties. This finding prompted research into the medication, with the U.S. FDA recently approving a ketamine-based nasal spray indicated for the management of depression. During the 2021 Festival of Neuroscience at the British Neuroscience Association, a whole session was devoted to talks on new research on understanding the substance’s mechanism of action and its possible use as an alcohol use disorder treatment. Professor Emma Robinson of the University of Bristol, who was the co-chair of…

ThursdaySep 23, 2021 9:03 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow…

WednesdaySep 22, 2021 1:45 pm

Canadian Company Takes Advantage of Psychedelics Popularity with Their New Beverage

Psychedelic Water is focused on capitalizing on the popularity of psychedelics with its kava-based drink. Kava is popular in the South Pacific, particularly in Fiji, which has it as its national drink. The Canadian beverage company asserts that its Psychedelic Water beverage is the first psychedelic blend of green tea leaf extract, damiana leaf and kava root in the world. The beverage isn’t hallucinogenic and has been developed to produce a calming sensation for a mood-boosting experience. The beverage is sponsored by Keith Stein and Pankaj Gogia, who discussed the potential for a psychedelic-based beverage after meeting through a mutual…

TuesdaySep 21, 2021 2:30 pm

Study Finds Intravenous Ketamine May Be Safely Used for Depression in Adolescents

A study has found that intravenous ketamine is effective in reducing symptoms of depression in the short term and is well tolerated among adolescents suffering from depression. Yale Child Study Center’s Jennifer B. Dwyer and her fellow researchers stated that case reports proposed early potential effectiveness of intranasal ketamine in bipolar depression and intravenous ketamine in depression in adolescents. The researchers also revealed that an intravenous (“IV”) ketamine open-label trial that was conducted recently, which recruited 13 adolescents with treatment-resistant depression, also proposed that ketamine could be efficacious in this population. However, the lack of placebo in the trial complicated…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000